# Raised cholesterol and triglycerides, and weight gain, on lorlatinib, bexarotene and elacestrant

Source: https://onco.cc/protocols/raised-lipids-and-weight-gain-on-lorlatinib-bexarotene-and-elacestrant/  
OnCo record `raised-lipids-and-weight-gain-on-lorlatinib-bexarotene-and-elacestrant` (Protocol). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Lorlatinib raises cholesterol and triglycerides (blood fats) in most people, often within weeks, and about three in ten gain weight. Bexarotene raises triglycerides sharply; elacestrant less often. Blood tests come before and during treatment, and a statin or similar medicine is often added. On lorlatinib or bexarotene, tell your team straight away about tummy or back pain, or being sick.

## Summary

Lorlatinib: in the US label, grade 3 or 4 rises in total cholesterol occurred in 18% and in triglycerides in 19% of 476 patients, with a median onset of 15 days, and 83% needed a lipid-lowering medicine started (median 17 days); the EU SmPC reports hypercholesterolaemia in 79.0% and hypertriglyceridaemia in 67.5%. Weight gain is listed in 31% (US) and 29.8% (EU). The reader's own team's protocol comes first.

Monitoring differs by label. US label: cholesterol and triglycerides before starting, at 1 and 2 months, then periodically. EU SmPC: before starting, at 2, 4 and 8 weeks, then regularly. Both say to start or increase lipid-lowering treatment; neither names a particular statin (the EU SmPC lists statins only as a class). The US label withholds lorlatinib only at grade 4 (until grade 2 or less, then the same dose; a reduced dose if severe hyperlipidaemia recurs). The EU SmPC prints the thresholds: lorlatinib continues at the same dose up to cholesterol 500 mg/dL (12.92 mmol/L) and triglycerides 1,000 mg/dL (11.4 mmol/L), and is withheld above them.

Which statin, and when, comes only from expert papers that Pfizer, the maker of lorlatinib, paid for. They prefer pitavastatin, pravastatin or rosuvastatin because of low involvement with CYP3A4, which lorlatinib induces. They disagree on when to start: at the first rise above normal (Bauer 2019, the Italian panel 2026) or by LDL cholesterol of 3.5 mmol/L or more and cardiovascular risk (the Canadian panel, Blais 2021).

Bexarotene: fasting lipids before treatment and weekly until the response is established (usually 2 to 4 weeks), then every 8 weeks (US label) or at least monthly (EU SmPC); keep triglycerides below 400 mg/dL (US) or 4.52 mmol/L (EU) to reduce the risk of what both labels call clinical sequelae (the US label points to its pancreatitis warning); both labels advise against gemfibrozil. The EU SmPC contraindicates bexarotene with a history of pancreatitis or uncontrolled lipids; the US label does not list those as contraindications.

Elacestrant: the US label asks for a lipid profile before and periodically during treatment (hypercholesterolaemia 30%, hypertriglyceridaemia 27%); the EU SmPC lists the rises as adverse reactions and has no monitoring instruction.

Weight gain on lorlatinib is managed with counselling at the start, diet and exercise, and referral to a nutritionist; the papers differ on dose changes and on GLP-1 medicines, for which they report no or limited data.

## Fields

- Kind: Protocol
- Last checked: 2026-11-18
- Also known as: hyperlipidaemia on lorlatinib; hyperlipidemia on lorlatinib; high cholesterol on lorlatinib; high triglycerides on lorlatinib; hypertriglyceridaemia on bexarotene; statins with lorlatinib; weight gain on lorlatinib; dyslipidaemia on elacestrant

## Connected records

- protocols: [Cognitive, mood and speech effects on lorlatinib, and cognitive effects on avapritinib](https://onco.cc/protocols/cognitive-and-mood-effects-on-lorlatinib-and-avapritinib/), [Diet, alcohol and weight during cancer treatment](https://onco.cc/protocols/diet-alcohol-and-weight-during-cancer-treatment/), [Drug, herbal and food interaction review for anticancer treatment](https://onco.cc/protocols/anticancer-drug-interaction-review/), [Fluid retention, swelling and pleural effusion on kinase inhibitors and MET-targeted drugs](https://onco.cc/protocols/fluid-retention-and-effusions-on-kinase-inhibitors/), [Heart risk assessment and monitoring before, during and after heart-toxic cancer treatment](https://onco.cc/protocols/cardio-oncology-risk-assessment-and-cardiac-surveillance/), [High blood sugar on PI3K, AKT and mTOR inhibitors: prevention, monitoring and treatment](https://onco.cc/protocols/hyperglycaemia-on-pi3k-akt-mtor-inhibitors/), [Pancreatitis and raised pancreatic enzymes on asciminib, ponatinib, nilotinib and bosutinib: monitoring, hold and stop rules](https://onco.cc/protocols/pancreatitis-and-raised-pancreatic-enzymes-on-targeted-drugs/)
- drugs: [Bexarotene](https://onco.cc/drugs/bexarotene/), [Elacestrant](https://onco.cc/drugs/elacestrant/), [Lorlatinib](https://onco.cc/drugs/lorlatinib/)
- terms: [CTCAE toxicity grading (grade 3-4 adverse events)](https://onco.cc/terms/ctcae-grading/), [Dose reduction, interruption and discontinuation](https://onco.cc/terms/dose-modification/)

---
JSON: https://onco.cc/api/v1/entities/raised-lipids-and-weight-gain-on-lorlatinib-bexarotene-and-elacestrant.json